Emgality

(galcanezumab)
1 ML galcanezumab-gnlm 100 MG/ML Prefilled Syringe [Emgality]1 ML galcanezumab-gnlm 120 MG/ML Auto-Injector [Emgality]
View 1 more
NO BLACK BOX WARNING

Dosage & administration

Most viewed Emgality resources

Letter of Medical Necessity - Migraine
Letter of Medical Necessity - Episodic Cluster Headache
Coverage Authorization Appeals - Migraine
Coverage Authorization Appeals - Episodic Cluster Headache
View more

drug label

Emgality prescribing information

Have more Emgality questions?

Submit MSL Request
Learn More

Need to report an Emgality issue?

ONLINE FORM
Report adverse event
Learn More

samples

Request Emgality samples

Online Sample Form
Learn More

prior authorization

Emgality Prior authorization resources

NOT PROVIDED BY BRAND
Complete Letter of Medical Necessity

NOT PROVIDED BY BRAND
Coverage Authorization Request

NOT PROVIDED BY BRAND
Complete Coverage Authorization appeals
Letter of Medical Necessity - Migraine
Letter of Medical Necessity - Episodic Cluster Headache
Coverage Authorization Appeals - Migraine
Coverage Authorization Appeals - Episodic Cluster Headache
Learn More

Benefits investigation

NOT PROVIDED BY BRAND
Benefits investigation resources
Learn More

Reimbursement help (FRM)

NOT PROVIDED BY BRAND
Reimbursement help (FRM) resources
Learn More

financial assistance

Emgality Financial assistance options

Co-pay savings program

commercial only
Enroll in patient savings program
Learn More

Bridge program

commercial only
Learn More

Foundation programs

under insured
no insurance
goverment insurance
65+
Lilly Cares Patient Assistance Program Application Online Form
Lilly Cares Patient Assistance Program Application - English
Lilly Cares Patient Assistance Program Application - Spanish
Learn More

patient education

Emgality Patient education

Getting started on Emgality

Instructions for Use (Video) : Episodic Cluster Headache
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Instructions for Use (Video): Migraine
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Instructions For Use : 100 mg syringe for Episodic Cluster Headache
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Instructions For Use: 120mg syringe for Migraine
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Instructions for Use : 120mg Pen for Migraine
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Patient toolkit

About Emgality
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Stories
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Emgality FAQs

What is the Pregnancy Exposure Registry for EMGALITY?The Pregnancy Exposure Registry is a program that monitors pregnancy outcomes in women who have been exposed to EMGALITY during pregnancy. It is designed to collect information on any potential risks to the developing fetus.
How can pregnant women enroll in the Pregnancy Exposure Registry?Pregnant women can enroll in the registry by calling 1-833-464-4724 or by contacting the company at www.migrainepregnancyregistry.com.
What is the estimated risk of major birth defects and miscarriage in the general population and among women with migraine?The estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively, in the general population. The estimated rate of major birth defects (2.2%-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine.
Are there any known risks associated with the use of EMGALITY during pregnancy?There are no adequate data on the developmental risk associated with the use of EMGALITY in pregnant women. However, animal studies have shown that administration of galcanezumab-gnlm to rats and rabbits during the period of organogenesis or to rats throughout pregnancy and lactation at plasma exposures greater than that expected clinically did not result in adverse effects on development.
Can EMGALITY be used during lactation?There are no data on the presence of galcanezumab-gnlm in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for EMGALITY and any potential adverse effects on the breastfed infant from EMGALITY or from the underlying maternal condition.
Is EMGALITY safe for pediatric use?Safety and effectiveness in pediatric patients have not been established.
Is there any difference in the response to EMGALITY in geriatric patients compared to younger patients?Clinical studies of EMGALITY did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.
FAQ Data Source

Can't find what you're looking for?

Our trained staff can help you:
Please note:
  • Access to a Field Reimbursement Manager (FRM) or Medical Science Liaison (MSL) varies by brand and may require talking with your rep first.
  • Samples are provided at the discretion of the brand.
  • We are unable to collect Protected Health Information (PHI), fill out forms, or submit them on your behalf.